A combination HER-2+ targeted approach achieved clinical remission with stable disease in our patient 46 months after she was diagnosed with LM metastases. However, spinal cord C-1 metastasis was not fully controlled with IT trastuzumab, ultimately leading to the patient’s respiratory compromise. In our patient, IT trastuzumab immunotherapy improved prognosis and was an effective strategy to manage HER-2+ LM disease. Given alone or alongside other anti-HER-2+ therapeutics with sufficient CNS penetration, IT trastuzumab could extend the lifespan of patients with leptomeningeal and CNS metastasis.
Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient [2015]
Nu T. Lu1,2, Jeffrey Raizer3, Erwin P. Gabor5, Natalie M. Liu2, James Q. Vu2, Dennis J. Slamon1,4 and John L. Barstis1,4*
http://www.immunotherapyofcancer.org...015-0084-y.pdf